Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Cisplatin
Drug ID BADD_D00474
Description Cisplatin, cisplatinum or cis-diamminedichloroplatinum(II) (CDDP) is a platinum-based chemotherapy drug used to treat various types of cancers, including sarcomas, some carcinomas (e.g. small cell lung cancer, and ovarian cancer), lymphomas and germ cell tumors. It was the first member of its class, which now also includes carboplatin and oxaliplatin.
Indications and Usage For the treatment of metastatic testicular tumors, metastatic ovarian tumors and advanced bladder cancer.
Marketing Status approved
ATC Code L01XA01
DrugBank ID DB00515
KEGG ID D00275
MeSH ID D002945
PubChem ID 5702198
TTD Drug ID D0U5HU
NDC Product Code 16729-288; 25021-253; 0143-9505; 68554-0077; 0143-9504; 68001-283; 44567-509; 50711-0001; 44567-510; 63323-103; 0703-5747; 0703-5748; 44567-530; 60505-6277; 68083-163; 44567-511; 49452-2078; 54875-0001; 67184-0010; 68083-162; 70860-206; 49812-0009; 72659-864
UNII Q20Q21Q62J
Synonyms Cisplatin | cis-Diamminedichloroplatinum(II) | Platinum Diamminodichloride | Diamminodichloride, Platinum | cis-Platinum | cis Platinum | Dichlorodiammineplatinum | cis-Diamminedichloroplatinum | cis Diamminedichloroplatinum | cis-Dichlorodiammineplatinum(II) | NSC-119875 | Platino | Platinol | Biocisplatinum | Platidiam
Chemical Information
Molecular Formula PtCl2(NH3)2
CAS Registry Number 15663-27-1
SMILES N.N.Cl[Pt]Cl
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Rash papular23.03.13.0170.000112%Not Available
Rash pruritic23.03.13.030--Not Available
Raynaud's phenomenon24.04.03.003--Not Available
Rectal haemorrhage24.07.02.018; 07.12.03.0010.000560%
Rectal ulcer07.04.01.0020.000112%
Renal disorder20.01.02.002--Not Available
Renal failure20.01.03.0050.001903%Not Available
Renal infarct24.01.11.004; 20.01.07.0080.000112%Not Available
Renal pain20.02.03.0030.000168%Not Available
Renal tubular disorder20.05.03.0040.000280%Not Available
Renal tubular necrosis20.01.07.0030.000716%Not Available
Respiratory distress22.02.01.0120.000504%Not Available
Respiratory failure22.02.06.002; 14.01.04.0030.001813%
Retching07.01.07.0020.000504%Not Available
Retinal artery occlusion06.10.01.005; 24.01.07.0030.000112%Not Available
Retinal pigmentation06.09.03.008--Not Available
Retinal vein occlusion24.01.07.006; 06.10.01.0100.000112%Not Available
Rhinorrhoea22.12.03.0210.000336%
Saliva altered07.06.01.0040.000168%Not Available
Salivary hypersecretion07.06.01.0090.000168%Not Available
Sarcoidosis10.02.06.0010.000336%Not Available
Scab23.03.03.0040.000168%Not Available
Second primary malignancy16.16.01.0140.000560%
Seizure17.12.03.001--
Sense of oppression08.01.09.0200.000112%Not Available
Shock24.06.02.0020.000280%Not Available
Sinus bradycardia02.03.03.0090.000168%
Sinus tachycardia02.03.03.0100.000672%
Skin exfoliation23.03.07.0030.000526%Not Available
Skin reaction10.01.03.019; 23.03.03.0130.000616%Not Available
The 11th Page    First    Pre   11 12 13 14 15    Next   Last    Total 20 Pages
ADReCS-Target
Drug Name ADR Term Target
Tip:  Drug Name  ADR Term  Protein  Variation  Gene